Market Access/ News/ News Consternation as NICE rejects Janssen MS drug Ponvory Phil Taylor HEOR, Janssen, Mayzent, multiple sclerosis, NHS, NICE, Novartis, Ponvory 0 Comment NICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, and it’s Share X Consternation as NICE rejects Janssen MS drug Ponvory https://pharmaphorum.com/news/consternation-as-nice-rejects-janssen-ms-drug-ponvory/
HEOR, Janssen, Mayzent, multiple sclerosis, NHS, NICE, Novartis, Ponvory
0 Comment
